- Home
- PAYS vs NBTX Comparison
PAYS vs NBTX Comparison
Compare PAYS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- NBTX
- Stock Information
- Founded
- PAYS 1995
- NBTX 2003
- Country
- PAYS United States
- NBTX France
- Employees
- PAYS N/A
- NBTX N/A
- Industry
- PAYS Business Services
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- PAYS Consumer Discretionary
- NBTX Health Care
- Exchange
- PAYS Nasdaq
- NBTX Nasdaq
- Market Cap
- PAYS 209.9M
- NBTX 201.9M
- IPO Year
- PAYS 1998
- NBTX 2020
- Fundamental
- Price
- PAYS $3.98
- NBTX $4.20
- Analyst Decision
- PAYS Strong Buy
- NBTX Strong Buy
- Analyst Count
- PAYS 3
- NBTX 2
- Target Price
- PAYS $6.17
- NBTX $11.50
- AVG Volume (30 Days)
- PAYS 147.3K
- NBTX 6.6K
- Earning Date
- PAYS 11-05-2024
- NBTX 11-19-2024
- Dividend Yield
- PAYS N/A
- NBTX N/A
- EPS Growth
- PAYS 368.11
- NBTX N/A
- EPS
- PAYS 0.14
- NBTX N/A
- Revenue
- PAYS $56,467,600.00
- NBTX $45,220,186.00
- Revenue This Year
- PAYS $24.07
- NBTX N/A
- Revenue Next Year
- PAYS $14.42
- NBTX N/A
- P/E Ratio
- PAYS $28.59
- NBTX N/A
- Revenue Growth
- PAYS 27.75
- NBTX 526.17
- 52 Week Low
- PAYS $2.20
- NBTX $4.07
- 52 Week High
- PAYS $5.59
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- PAYS 55.13
- NBTX 40.06
- Support Level
- PAYS $3.81
- NBTX $4.07
- Resistance Level
- PAYS $4.09
- NBTX $4.44
- Average True Range (ATR)
- PAYS 0.15
- NBTX 0.22
- MACD
- PAYS 0.05
- NBTX -0.03
- Stochastic Oscillator
- PAYS 80.36
- NBTX 13.00
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized, payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.